Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bioheng Granted US Orphan Drug Status for Universal CAR-T Therapy

publication date: Jun 21, 2021

Nanjing Bioheng Biotech reported its universal CAR-T cell therapy was granted US Orphan Drug Designation to treat T-cell acute lymphoblastic leukemia. Bioheng's pipelines include the allogeneic CAR-T, which is used for hematologic and solid tumors. The company says a universal product solves the drawbacks of high cost and a long wait to develop an individual CAR T therapy. Earlier this year, Bioheng raised $80 million in Series B Financing co-led by GL Ventures, the venture capital unit of Hillhouse Capital, Decheng Capital and Octagon Capital. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China